{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T23:14:28Z","timestamp":1783293268655,"version":"3.54.6"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128722","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:15:22Z","timestamp":1778933722000},"page":"128722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression"],"prefix":"10.1016","volume":"85","author":[{"given":"Tu P.H.","family":"Trang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes T.","family":"Bazelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf H.","family":"Klungel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie H.","family":"Bots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128722_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41541-023-00681-3","article-title":"Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination","volume":"8","author":"Katoto","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128722_bb0010","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2026.128722_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004245","article-title":"Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: a self-controlled case series analysis in England","volume":"20","author":"Stowe","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/22221751.2022.2050952","article-title":"Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study","volume":"11","author":"Lai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2026.128722_bb0025","unstructured":"Douglas Altman et al. in Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (ed Julian PT Higgins Jonathan J Deeks, Douglas G Altman; on behalf of the Cochrane Statistical Methods Group) (2023)."},{"key":"10.1016\/j.vaccine.2026.128722_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2022.08.012","article-title":"Understanding variation in the results of real-world evidence studies that seem to address the same question","volume":"151","author":"Wang","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0040","article-title":"Vaccine safety surveillance using routinely collected healthcare data-an empirical evaluation of epidemiological designs","volume":"13","author":"Schuemie","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0050","author":"FDA Office of Media Affairs"},{"key":"10.1016\/j.vaccine.2026.128722_bb0055","unstructured":"EndNote (Clarivate, Philadelphia, PA, 2013)."},{"key":"10.1016\/j.vaccine.2026.128722_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"van de Schoot","year":"2021","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.vaccine.2026.128722_bb0065","author":"ASReview"},{"key":"10.1016\/j.vaccine.2026.128722_bb0070","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128722_bb0075","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000709","article-title":"Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data","volume":"3","author":"Heyard","year":"2024","journal-title":"BMJ Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0085","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/biom.13197","article-title":"Optimal approximate conversions of odds ratios and hazard ratios to risk ratios","volume":"76","author":"VanderWeele","year":"2019","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2026.128722_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2026.128722_bb0095","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jrsm.1310","article-title":"Dealing with effect size multiplicity in systematic reviews and meta-analyses","volume":"9","author":"L\u00f3pez-L\u00f3pez","year":"2018","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vaccine.2026.128722_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128722_bb0105","unstructured":"Page MJ, H. J., Sterne JAC. in Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (ed Thomas J Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors)) Ch. 13, (Cochrane, 2023)."},{"key":"10.1016\/j.vaccine.2026.128722_bb0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/1750984X.2021.1946835","article-title":"Handling effect size dependency in meta-analysis","volume":"15","author":"Gucciardi","year":"2022","journal-title":"Int Rev Sport Exerc Psychol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jrsm.6","article-title":"Graphical displays for meta-analysis: an overview with suggestions for practice","volume":"1","author":"Anzures-Cabrera","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vaccine.2026.128722_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11121-021-01246-3","article-title":"Meta-analysis with robust variance estimation: expanding the range of working models","volume":"23","author":"Pustejovsky","year":"2022","journal-title":"Prev Sci"},{"key":"10.1016\/j.vaccine.2026.128722_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jrsm.1091","article-title":"Robust variance estimation with dependent effect sizes: practical considerations including a software tutorial in Stata and SPSS","volume":"5","author":"Tanner-Smith","year":"2014","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vaccine.2026.128722_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1037\/met0000434","article-title":"Centering categorical predictors in multilevel models: best practices and interpretation","volume":"28","author":"Yaremych","year":"2023","journal-title":"Psychol Methods"},{"key":"10.1016\/j.vaccine.2026.128722_bb0135","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1016\/j.vaccine.2022.05.048","article-title":"Myocarditis and\/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines","volume":"40","author":"Abraham","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128722_bb0140","article-title":"Safety of BA.4\u20135 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128722_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070483","article-title":"Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study","volume":"378","author":"Andersson","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128722_bb0150","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1038043","article-title":"Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: a population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries","volume":"13","author":"Bots","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-022-07823-3","article-title":"Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy","volume":"22","author":"Corrao","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128722_bb0165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamainternmed.2022.2109","article-title":"Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US veterans","volume":"182","author":"Dickerman","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0170","article-title":"Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) COVID-19 vaccination: a self-controlled cases series and a case-control study","volume":"35","author":"Fan","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2026.128722_bb0175","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","article-title":"Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination","volume":"40","author":"Goddard","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128722_bb0180","doi-asserted-by":"crossref","first-page":"e2326852","DOI":"10.1001\/jamanetworkopen.2023.26852","article-title":"Comparative risks of potential adverse events following COVID-19 mRNA vaccination among older US adults","volume":"6","author":"Harris","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128722_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study","volume":"375","author":"Husby","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128722_bb0190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab663","article-title":"A small but significantly greater incidence of inflammatory heart disease identified after vaccination for Severe Acute Respiratory Syndrome Coronavirus 2","volume":"9","author":"Knowlton","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128722_bb0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M21-3700","article-title":"Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study","volume":"175","author":"Lai","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004056","article-title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study","volume":"19","author":"Massari","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0210","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0215","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jacc.2022.08.799","article-title":"Comparative risk of myocarditis\/pericarditis following second doses of BNT162b2 and mRNA-1273 coronavirus vaccines","volume":"80","author":"Naveed","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004127","article-title":"Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the Omicron variant in 0.8 million adolescents: a nationwide cohort study in Sweden","volume":"20","author":"Nordstr\u00f6m","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0230","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","article-title":"Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex","volume":"146","author":"Patone","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2026.128722_bb0235","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2022.05.075","article-title":"Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: a self-controlled case series study","volume":"40","author":"Ab Rahman","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128722_bb0240","article-title":"BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12\u201317 years in Scotland","volume":"23","author":"Rudan","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.128722_bb0245","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1016\/j.vaccine.2023.06.014","article-title":"Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: two self-controlled studies in the U.S.","volume":"41","author":"Shoaibi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128722_bb0250","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010617","article-title":"Risk of worsening heart failure and all-cause mortality following COVID-19 vaccination in patients with heart failure: a nationwide real-world safety study","volume":"16","author":"Sindet-Pedersen","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.vaccine.2026.128722_bb0255","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2666-7568(22)00125-8","article-title":"Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series","volume":"3","author":"Wan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.vaccine.2026.128722_bb0260","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S2213-2600(22)00407-6","article-title":"Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study","volume":"11","author":"Yechezkel","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0265","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S1473-3099(23)00207-4","article-title":"Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study","volume":"23","author":"Yamin","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128722_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31401-5","article-title":"Age and sex-specific risks of myocarditis and pericarditis following COVID-19 messenger RNA vaccines","volume":"13","author":"Le Vu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128722_bb0275","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.clinthera.2024.06.005","article-title":"Current approaches in postapproval vaccine safety studies using real-world data: a systematic review of published literature","volume":"46","author":"Wu","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2026.128722_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837632","article-title":"Current approaches to vaccine safety using observational data: a rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) study design","volume":"13","author":"Lai","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-statistics-030718-105108","article-title":"Self-controlled case series methodology","volume":"6","author":"Whitaker","year":"2019","journal-title":"Annu Rev Stat Appl"},{"key":"10.1016\/j.vaccine.2026.128722_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0278-0","article-title":"Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review","volume":"17","author":"Gault","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2022.2020108","article-title":"Self-controlled case series design in vaccine safety: a systematic review","volume":"21","author":"Nie","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128722_bb0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0962280208092342","article-title":"The methodology of self-controlled case series studies","volume":"18","author":"Whitaker","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.vaccine.2026.128722_bb0305","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jclinepi.2005.11.012","article-title":"Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations","volume":"59","author":"Glanz","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0310","doi-asserted-by":"crossref","first-page":"389","DOI":"10.15585\/mmwr.mm7011e2","article-title":"COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons - United States, December 14, 2020-February 14, 2021","volume":"70","author":"Kriss","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128722_bb0315","article-title":"Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents","author":"Tsang","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.vaccine.2026.128722_bb0320","series-title":"Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU\/EEA, 6 May 2021","author":"European Centre for Disease Prevention and Control","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128722_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00789-6","article-title":"Risk of carditis among adolescents after extending the interdose intervals of BNT162b2","volume":"9","author":"Fan","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128722_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-52038-6","article-title":"Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis","volume":"15","author":"Le Vu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128722_bb0335","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/sim.4125","article-title":"Identifying optimal risk windows for self-controlled case series studies of vaccine safety","volume":"30","author":"Xu","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0340","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128722_bb0345","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/sta4.166","article-title":"Bias and estimation under misspecification of the risk period in self-controlled case series studies","volume":"6","author":"Campos","year":"2017","journal-title":"Stat Oxf"},{"key":"10.1016\/j.vaccine.2026.128722_bb0350","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/sim.5733","article-title":"A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design","volume":"32","author":"Xu","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0355","article-title":"Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example","author":"Bots","year":"2024","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128722_bb0360","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128722_bb0365","first-page":"49","article-title":"Development of minimum reporting sets of patient characteristics in epidemiological research: a methodological systematic review","volume":"5","author":"Vuong","year":"2023","journal-title":"Res Meth Med Health Sci"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:26:37Z","timestamp":1783290397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":73,"alternative-id":["S0264410X26005311"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128722","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128722"}}